Estrella Immunopharma, Inc. (ESLAW)
US Markets · Healthcare · Biotechnology
$0.07
-10.93%
Closing price as of 2026-09-11 · Source: TEK2day Finance
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.8M) | (613K) | (2.3M) | (2.1M) |
| Net Income | (4.8M) | (613K) | (2.3M) | (2.3M) |
Annual Financials
| Metric | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.7M) | (11.1M) | (7.3M) | (13.1M) |
| Net Income | (1.7M) | (11.1M) | (7.3M) | (13.1M) |